In U2OS cells, 100 nM spliceostatin A preserved early repair-factor recruitment after irradiation. Longer exposure induced DNA damage: after 48 h, the comet response and γH2AX induction were reversed by RNaseH1 expression, supporting an R-loop-associated effect. These results depend on exposure duration and endpoint. [2]
In a human RPE1 reporter model, 30 µM spliceostatin A treatment before serum starvation was associated with fewer primary cilia and more cycling cells than DMSO controls. This qualitative phenotype does not establish a ciliogenesis-specific molecular target. [3]
Splicing inhibition and heparin-sensitive U2 snRNP assembly
Biochemical assay · HeLa nuclear extracts with model AdML pre-mRNA or its 3′ region [1]
SSA inhibited splicing and accumulation of heparin-resistant A complexes. Without heparin, ATP-dependent U2-containing complexes still formed; this supports weakened assembly rather than universal prevention of initial U2 recruitment.
Literature-Reported Treatment Conditions
- Treatment concentration
- Splicing/assembly concentration series as labeled in Figs 1–2; 88.8 nM SSA in Fig 2B
- Exposure duration
- Splicing: 1 h; assembly: 15 min before heparin challenge
- Method
- Denaturing splicing gels and native complex assembly gels at 30°C
- Vehicle
- Methanol carrier control
- Reported limits
- No IC50, replicate count or statistical uncertainty assigned to gel-derived inhibition thresholds.
Methods and source locations
Compound reported in the paper: Spliceostatin A; Compound label in the paper: SSA
Compound-level cell-free mechanism; no supplier/lot inference.
Figs 1A–C, 2A–D; corresponding Results; Materials and methods: in vitro splicing assays and spliceosome assembly
Accumulation of splicing intermediates/products: AdML pre-mRNA splicing, denaturing PAGE — Results: Effects of SSA on spliceosome assembly; Fig 1A
U2 snRNP-containing complexes: Native gels with/without heparin; ATP and U2-inactivation controls — Fig 2A–D and caption; Results: SSA destabilizes U2 snRNP assembly
Selective loss of SF3b155–pre-mRNA contact
Biochemical assay · HeLa nuclear extracts and labeled AdML 3′ RNA [1]
SSA decreased SF3b155 cross-linking to pre-mRNA while U2AF65 and SF3a60 contacts were retained. U2 snRNA–pre-mRNA cross-linking was largely unaffected.
Literature-Reported Treatment Conditions
- Treatment concentration
- 88 nM for UV protein cross-linking; 53 or 267 nM in psoralen RNA cross-linking
- Exposure duration
- UV assay: 30 min incubation before irradiation
- Method
- UV cross-linking followed by immunoprecipitation; psoralen RNA–RNA cross-linking
- Vehicle
- Methanol
- Reported limits
- No direct binding affinity or stoichiometry measured here.
Methods and source locations
Compound reported in the paper: Spliceostatin A; Compound label in the paper: SSA
Interaction assay supports perturbation of SF3b-associated RNA contacts, not direct binding affinity.
Fig 3A–C and caption; Results: SSA leads to altered RNA–protein and RNA–RNA interactions; Materials and methods: UV cross-linking and immunoprecipitation
Protein–pre-mRNA cross-linking specificity: UV cross-linking/immunoprecipitation with methanol and mock/U2-inactivated extract controls — Fig 3A and caption; corresponding Results
U2 snRNA–pre-mRNA cross-linking: Psoralen cross-linking; RNA identity checked by RNase H analysis — Fig 3B–C and caption; corresponding Results
Preserved early repair-factor recruitment after irradiation
Cell-based study · Human U2OS osteosarcoma cells [2]
At 100 nM SSA, early irradiation-induced RAD51, BRCA1, RPA and pATM foci recruitment was retained relative to DMSO; isoginkgetin impaired these responses in the same comparison.
Literature-Reported Treatment Conditions
- Treatment concentration
- 100 nM
- Exposure duration
- 24 h pretreatment, then 2 h after irradiation
- Method
- Immunofluorescence after 2 Gy irradiation; matched unirradiated controls
- Vehicle
- DMSO
- Reported limits
- No exact plotted percentages inferred. Figure caption reports two–three independent experiments collectively, without per-panel n assignment.
Methods and source locations
Compound reported in the paper: Spliceostatin A; Compound label in the paper: SSA
Condition-specific cellular limiting evidence; not general absence of DNA damage.
Fig 3B and caption; Results: Splicing inhibition reduces HR through attenuating transcription; cell culture/transfection methods
RAD51, BRCA1, RPA and pATM foci after irradiation: More than 400 cells per quantification; thresholds >12 foci for each named marker; figure-level s.e.m. from two–three independent experiments — Fig 3B and caption; corresponding Results
RNaseH1-sensitive DNA damage after prolonged SSA exposure
Cell-based study · Human U2OS cells with GFP-empty-vector or ectopic RNaseH1 expression [2]
SSA increased alkaline-comet DNA damage after 48 h. RNaseH1 expression reversed the comet response and rescued γH2AX induction, supporting an R-loop-associated component.
Literature-Reported Treatment Conditions
- Treatment concentration
- 100 nM
- Exposure duration
- 48 h for SSA comet assay; western time course 0, 24, 48, 72 h
- Method
- Alkaline comet assay and immunoblotting; RNaseH1 rescue compared with empty vector
- Vehicle
- DMSO
- Reported limits
- Fig 6d y-axis is tail moment, despite caption describing tail length; use methods definition. Exact effect size not tabulated in the read material.
Methods and source locations
Compound reported in the paper: Spliceostatin A; Compound label in the paper: SSA
Cellular DNA-damage result with a rescue control; not an animal efficacy result.
Fig 6C–F and caption; Results: DNA damage caused by SNRPA1 depletion and SSA treatment; Comet assay and cell culture methods
Alkaline-comet tail moment: Tail moment = percent DNA in tail × tail length; methods: at least 200 comets per sample; caption n=200, three independent experiments, s.e.m. — Fig 6C–D and caption; Comet assay methods
γH2AX induction: Immunoblots with H2AX and β-actin controls — Fig 6E–F and caption; corresponding Results
Reduced primary-cilium formation after SSA treatment
Cell-based study · SEMG-hTERT-RPE1 cells expressing Smo-EGFP and mCherry-Geminin [3]
SSA-treated cells showed fewer cilia and more cycling cells than DMSO controls after serum starvation. Figure 4B provides representative images rather than a numerical dose–response.
Literature-Reported Treatment Conditions
- Treatment concentration
- 30 µM
- Exposure duration
- 24 h treatment before 48 h serum starvation; persistence of SSA during starvation is not explicit
- Method
- Fluorescence microscopy of Smo-EGFP-positive cilia and mCherry-Geminin-positive cycling cells
- Vehicle
- DMSO
- Reported limits
- Cell-treatment solvent percentage, washout/persistence during starvation, and panel-specific n not explicit in adopted text/caption.
Methods and source locations
Compound reported in the paper: Spliceostatin A; Compound label in the paper: SSA
Compound-level cell phenotype; paper-level catalog match does not validate current Adooq lots.
Fig 4A–B and caption; Results: Inhibition of mRNA splicing causes ciliary defects; Cell culture and cellular image analysis methods
Cilia and cycling-cell phenotype under serum starvation: Representative fluorescence images; no exact cell percentages extracted — Fig 4A–B; corresponding Results